Pfizer RSV vaccine prevents severe infection
Pfizer is working on an experimental RSV vaccine they say was found effective in preventing severe infections in infants.
If approved, Pfizer’s shot could be the first maternal vaccine available to prevent the disease in young infants.
Pfizer plans to file for approval by the end of the year.
However, the company so far is seeing one drawback. The vaccine did not meet the study’s second main goal of preventing more moderate forms of the illness.